MGRM:NSD-Monogram Orthopaedics Inc. Common Stock (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 2.47

Change

+0.02 (+0.82)%

Market Cap

USD 0.09B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Monogram Technologies Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Orthopaedics, Inc. and changed its name to Monogram Technologies Inc. in May 2024. Monogram Technologies Inc. was founded in 2015 and is headquartered in Austin, Texas.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.67 (-0.84%)

USD 31.67B
PODD Insulet Corporation

-0.95 (-0.35%)

USD 18.68B
MASI Masimo Corporation

+0.52 (+0.31%)

USD 9.17B
BRKR Bruker Corporation

-1.69 (-2.68%)

USD 9.05B
PRCT Procept Biorobotics Corp

-0.91 (-1.10%)

USD 4.70B
NARI Inari Medical Inc

-0.04 (-0.05%)

USD 4.64B
NVCR Novocure Ltd

-1.15 (-4.18%)

USD 3.27B
QDEL Quidel Corporation

-3.51 (-7.87%)

USD 2.98B
IRTC iRhythm Technologies Inc

+4.42 (+4.67%)

USD 2.78B
LIVN LivaNova PLC

+0.31 (+0.66%)

USD 2.57B

ETFs Containing MGRM

SHLD Global X Funds 4.22 % 0.00 %

+0.37 (+0.98%)

USD 0.67B
EEA:PA BNP Paribas Easy FTSE EPR.. 4.11 % 0.00 %

+0.02 (+0.98%)

USD 0.08B
EEE:PA BNP Paribas Easy FTSE EPR.. 4.11 % 0.00 %

+0.02 (+0.98%)

USD 0.11B
EEAA:XETRA BNP Paribas Easy FTSE EPR.. 4.11 % 0.00 %

+0.03 (+0.98%)

USD 0.20B
CIBR First Trust NASDAQ Cybers.. 3.69 % 0.00 %

+0.44 (+0.98%)

USD 7.46B
EMIF iShares Emerging Markets .. 0.00 % 0.75 %

+0.37 (+0.98%)

USD 8.38M
UAE iShares MSCI UAE ETF 0.00 % 0.59 %

-0.01 (0.98%)

USD 0.07B
EEAA:F BNP Paribas Easy - FTSE E.. 0.00 % 0.00 %

N/A

N/A
IM2A:F BNP Paribas Easy - FTSE E.. 0.00 % 0.00 %

-0.03 (0.98%)

N/A
IM2A:XETRA BNP Paribas Easy - FTSE E.. 0.00 % 0.00 %

+0.02 (+0.98%)

USD 0.20B
IQQP:XETRA iShares European Property.. 0.00 % 0.00 %

+0.13 (+0.98%)

USD 1.33B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.22% 67% D+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.22% 67% D+ 81% B-
Trailing 12 Months  
Capital Gain -29.43% 41% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.43% 41% F 26% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.56% 25% F 18% F
Dividend Return -12.56% 25% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.56% 99% N/A 78% C+
Risk Adjusted Return -64.20% 13% F 10% F
Market Capitalization 0.09B 48% F 36% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector